| 药品名称 | 药品通用名称：氯化钾注射液 英文名/拉丁名：Potassium Chloride Injection | | --- | --- | | 剂型 | 注射剂 | | 注册分类 | 化学药品 | | 规格 | 10ml:1.5g | | 证书编号 | 2025B03884 | | 药品批准文号 | 国药准字 H20258168 | | 申请事项 | 增加 规格，同时申请仿制药质量和疗效 10ml:1.5g | | | 一致性评价 | 证券代码：600062 证券简称：华润双鹤 公告编号：临 2025－077 华润双鹤药业股份有限公司 关于全资子公司安徽双鹤药业有限责任公司 氯化钾注射液获得药品补充申请批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 整性承担法律责任。 近日，华润双鹤药业股份有限公司(以下简称"公司")全资子公司 安徽双鹤药业有限责任公司(以下简称"安徽双鹤")收到了国家药品监 督管理局(以下简称"国家药监局")颁发的氯化钾注射液(以下简称"该 药品")《药品补充申请批准通知书》。现将相关情况公告如 ...

华润双鹤药业股份有限公司 一、会议时间： 1、现场会议召开时间：2025 年 9 月 9 日(星期二)上午 9 点 00 分 2、网络投票时间：2025 年 9 月 9 日，采用上海证券交易所网络 投票系统，通过交易系统投票平台的投票时间为股东会召开当日的交 易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互联网投票 平台的投票时间为股东会召开当日的 9:15-15:00。 二、会议地点： 1、现场会议地点：北京市朝阳区锐创国际中心 A 座 9 层会议室 2025 年第二次临时股东会会议文件 2025 年 9 月 9 日 2025 年第二次临时股东会 2025 年 9 月 9 日 2025 年第二次临时股东会会议议程 2、网络投票平台：上海证券交易所股东会网络投票系统 | 三、会议议程： | | --- | | 序号 | 审议内容 | | --- | --- | | 1 | 关于 年半年度利润分配的议案 2025 | | 2 | 关于公司符合公开发行公司债券条件的议案 | | 3.00 | 关于公开发行公司债券方案的议案 | | 3.01 | 发行规模 | | 3.02 | ...

Core Viewpoint - China Resources Double Crane (华润双鹤) announced that its wholly-owned subsidiary, Anhui Double Crane Pharmaceutical Co., Ltd., has received the approval notice for the supplementary application of potassium chloride injection from the National Medical Products Administration. This product is used for the treatment and prevention of hypokalemia, particularly when oral potassium supplementation is not feasible [1]. Company Summary - The approval for potassium chloride injection marks a significant milestone for Anhui Double Crane Pharmaceutical, enhancing its product portfolio in the pharmaceutical market [1]. - The total R&D investment for potassium chloride injection by Anhui Double Crane has reached 1.6109 million RMB (approximately 0.161 million USD) as of the date of the announcement [1]. Industry Summary - The potassium chloride injection is critical for addressing hypokalemia, a condition that can arise in various clinical settings, indicating a steady demand for such pharmaceutical products in the healthcare industry [1].

Group 1 - The core point of the article is that China Resources Double Crane Pharmaceutical Co., Ltd. announced that its wholly-owned subsidiary, Anhui Double Crane Pharmaceutical Co., Ltd., has received the approval notice for the supplementary application of potassium chloride injection from the National Medical Products Administration [1]

Core Viewpoint - China Resources Double Crane Pharmaceutical Co., Ltd. (华润双鹤) announced that its wholly-owned subsidiary, Anhui Double Crane Pharmaceutical Co., Ltd. (安徽双鹤), received the approval notice for the supplementary application of potassium chloride injection from the National Medical Products Administration (国家药监局) [1] Group 1 - The approval includes an additional specification of 10ml:1.5g for potassium chloride injection, which has passed the consistency evaluation of generic drug quality and efficacy [1] - Potassium chloride injection is used for the treatment and prevention of hypokalemia, particularly when oral potassium supplementation is not feasible [1] - The approval is expected to enhance future market sales and competition, while also providing valuable experience for subsequent consistency evaluations of generic drugs [1]

Core Viewpoint - China Resources Double Crane Pharmaceutical (600062.SH) announced that its wholly-owned subsidiary, Anhui Double Crane Pharmaceutical Co., Ltd., received the approval notice from the National Medical Products Administration for the potassium chloride injection, which includes a new specification of 10ml:1.5g [1] Group 1 - The potassium chloride injection is used for the treatment and prevention of hypokalemia, particularly when oral potassium supplementation is not feasible [1] - The approval of the potassium chloride injection will enhance future market sales and competition, while also providing valuable experience for subsequent consistency evaluations of generic drugs [1]

华润双鹤公告，全资子公司安徽双鹤药业有限责任公司收到国家药监局颁发的氯化钾注射液《药品补充 申请批准通知书》。该药品用于治疗和预防低钾血症，安徽双鹤现有氯化钾注射液(10ml:1g)，此次获批 增加10ml:1.5g规格，累计研发投入为161.09万元人民币。2024年氯化钾注射液全球销售额为2.23亿美 元，国内医疗市场和零售市场销售总额为6.17亿元人民币。公司氯化钾注射液2024年销售收入为96万 元。 ...

Core Viewpoint - China Resources Double Crane announced that its wholly-owned subsidiaries have received drug registration certificates for several medications from the National Medical Products Administration [1] Group 1: Company Developments - Beijing Wanhui Double Crane Pharmaceutical Co., Ltd., China Resources Double Crane Limin Pharmaceutical (Jinan) Co., Ltd., and Double Crane Pharmaceutical (Hainan) Co., Ltd. have each received drug registration certificates for Amlodipine Benazepril Capsules, Tocilizumab Sustained-Release Tablets, and Valsartan Fumarate Tablets respectively [1]

Policy Developments - The State Council aims to develop the China (Jiangsu) Pilot Free Trade Zone into a globally influential biopharmaceutical industry hub, with a plan that includes 18 key tasks for integrated innovation across the entire industry chain by 2030 [1] Drug Approvals - China Resources Double Crane announced that its subsidiaries received drug registration certificates for three products, which will enhance the company's product line and market competitiveness [2] - Tianyao Pharmaceutical's subsidiary received a drug registration certificate for a new eye drop product, which is expected to positively impact the company's domestic market expansion and performance [3] Financial Reports - China National Pharmaceutical Group reported a revenue of 17.076 billion yuan for the first half of 2025, a decrease of 6.71% year-on-year, with a net profit of 294 million yuan, down 16.19% [4] - Jiahe Meikang reported a revenue of 219 million yuan for the first half of 2025, a decline of 27.22%, resulting in a net loss of 116 million yuan [5] - Renfu Pharmaceutical reported a revenue of 12.064 billion yuan, a decrease of 6.20%, but a net profit increase of 3.92% to 1.155 billion yuan [6] Investment Activities - Tibet Pharmaceutical plans to invest 60 million USD in Accuredit Therapeutics Limited, acquiring a 40.82% stake, focusing on gene editing technologies [7] Industry Developments - The first long-acting injection for infertility treatment has been approved, providing a more efficient and convenient option for patients compared to traditional daily injections [8] - A study revealed a protein linked to infertility and cancer, suggesting potential new treatment avenues for both conditions [9] Shareholder Actions - Dabo Medical announced a plan for a shareholder to reduce their stake by up to 2% of the company's shares [10] - Kangchen Pharmaceutical's executive plans to sell up to 87,500 shares due to personal financial needs [11]

Group 1 - The company, China Resources Double Crane, announced the receipt of the drug supplement approval notice for Metoclopramide Hydrochloride Injection from the National Medical Products Administration [2] - The company also received the drug registration certificate for Lidocaine and Prilocaine Cream [2]